Jounce Therapeutics, Inc. (JNCE): history, ownership, mission, how it works & makes money

A Brief History of Jounce Therapeutics, Inc. (JNCE)

Foundation and Early Years

Jounce Therapeutics, Inc. was founded in 2015, focusing on discovering and developing immunotherapeutic treatments for cancer. The founding team, which included recognized leaders in immuno-oncology, aimed to leverage insights from the immune system to create therapies capable of improving patient outcomes.

Initial Public Offering (IPO)

On June 30, 2017, Jounce Therapeutics went public, raising approximately $96 million through its initial public offering. The shares were priced at $15 per share during the IPO.

Key Product Developments

The company’s lead product candidate, JTX-2011, is a monoclonal antibody that targets PD-1. Clinical trials for JTX-2011 began in 2018, aiming at treating patients with various solid tumors.

In 2020, Jounce released results from a Phase 1 clinical trial of JTX-2011, reporting an overall response rate of 23% in patients with advanced solid tumors.

Strategic Partnerships

In 2019, Jounce entered a collaboration agreement with Celgene Corporation to develop and commercialize JTX-2011, further solidifying its position in the biopharmaceutical industry. This collaboration was valued at up to $1.6 billion including upfront payments and potential milestones.

Recent Developments

As of 2022, Jounce Therapeutics has expanded its pipeline to include JTX-4014, a dual checkpoint inhibitor. The company announced a strategic review of its assets in 2023, indicating potential restructuring or refocusing efforts to optimize its portfolio.

Financial Performance

As of the end of Q3 2023, Jounce reported total revenues of approximately $15.8 million, with a net loss of $28.4 million for the first nine months of the year. The company’s cash and cash equivalents stood at $53.7 million.

Market Position and Future Outlook

Jounce Therapeutics continues to position itself within the competitive landscape of immuno-oncology. The focus remains on advancing its clinical programs and potential partnerships to drive growth and innovation in cancer treatment.

A Who Owns Jounce Therapeutics, Inc. (JNCE)

Current Ownership Structure

As of the latest available data, Jounce Therapeutics, Inc. (JNCE) has a diverse ownership structure consisting of institutional investors, insiders, and retail shareholders. Below is a comprehensive breakdown of the ownership:

Major Institutional Shareholders

The following institutions are among the largest shareholders of Jounce Therapeutics, Inc.:

Insider Ownership Details

Insider ownership provides insight into the confidence that executives have in the company. The following table highlights key insiders and their respective shareholdings:

Recent Market Activity

Jounce Therapeutics, Inc. has experienced fluctuations in stock price recently. Below are the statistics from the latest quarter:

Shareholder Meetings and Voting Rights

Shareholders of Jounce Therapeutics, Inc. exercise their voting rights at annual and special meetings. Key voting rights include:

• Election of Board Members
• Approval of Mergers and Acquisitions
• Amendments to Corporate Governance

Recent Shareholder Communications

Jounce Therapeutics, Inc. communicates with its shareholders through various channels, including:

• Quarterly Earnings Reports
• Annual Proxy Statements
• Investor Webinars

Future Outlook and Shareholder Value

Ongoing developments in Jounce Therapeutics' pipeline and strategic partnerships are expected to impact shareholder value positively. The financial projections indicate:

Jounce Therapeutics, Inc. (JNCE) Mission Statement

Overview

Jounce Therapeutics, Inc. is a biotechnology company focused on the development of cancer immunotherapies. The company's mission statement articulates its commitment to transforming the treatment landscape for patients with cancer through innovative therapies.

Mission Statement

The mission of Jounce Therapeutics is to deliver transformative therapies to patients with cancer by leveraging its proprietary Jounce Immune Oncological Platform. This platform is designed to enhance the immune system's ability to recognize and destroy tumors.

Strategic Goals

• Developing innovative treatments that significantly improve patient outcomes.
• Advancing multiple programs in its pipeline targeting various cancer types.
• Collaborating with leading academic and industrial partners to enhance research and development.

Current Pipeline

Financial Overview

As of the latest fiscal year-end, Jounce Therapeutics reported the following financial metrics:

Market Capitalization

As of October 2023, Jounce Therapeutics has a market capitalization of approximately $250 million.

Recent Developments

• Announced a partnership with a leading pharmaceutical company to co-develop a novel immunotherapy.
• Presented findings at the American Association for Cancer Research (AACR) Annual Meeting 2023.
• Received Fast Track Designation from the FDA for JTX-1811.

Corporate Governance

Jounce Therapeutics is committed to high standards of corporate governance, adhering to the following principles:

• Transparency in operations and decision-making.
• Accountability to shareholders and stakeholders.
• Ethical conduct in all business dealings.

How Jounce Therapeutics, Inc. (JNCE) Works

Company Overview

Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company focused on discovering and developing treatments for cancer. The company employs a proprietary platform that evaluates the immune system's response to tumors. As of Q3 2023, Jounce is headquartered in Cambridge, Massachusetts.

Business Model

The business model of Jounce Therapeutics is based on the development of antibody-based therapies aimed at modulating the immune system to treat cancer. Jounce conducts research through its Jounce Discovery platform, which is designed to identify and develop therapeutic candidates that enhance the immune response against tumors.

Financial Performance

As of Q3 2023, Jounce Therapeutics reported total revenue of $14.2 million for the fiscal year. The company's operating expenses for the same period were approximately $25.3 million, leading to a net loss of $11.1 million. The company had cash, cash equivalents, and marketable securities totaling $85.6 million as of September 30, 2023.

Research and Development

Jounce's research and development efforts focus primarily on its lead product candidate, JTX-1811, an anti-PD-1 monoclonal antibody. The company is also advancing several other candidates within its pipeline, which are at various stages of clinical development.

Clinical Trials

As of October 2023, Jounce Therapeutics has initiated multiple clinical trials for its products. The Phase 1 trial of JTX-1811 began in early 2023 with the aim to evaluate its safety, tolerability, and preliminary efficacy in patients with advanced solid tumors.

Market Position

Jounce Therapeutics operates in a competitive landscape of biopharmaceutical companies focused on oncology. As of Q3 2023, its market capitalization was approximately $300 million, reflecting its position in the sector amidst ongoing clinical developments and collaborations.

Collaborations and Partnerships

The company has established strategic collaborations with prominent organizations to enhance its drug discovery and clinical development capabilities. Notable collaborations include partnerships with large pharmaceutical firms for potential co-development and commercialization of therapies.

• Collaboration with Bristol-Myers Squibb
• Partnership with Merck
• Alliance with Roche

Future Outlook

Jounce Therapeutics aims to expand its pipeline through ongoing clinical trials and potential new drug candidates. The company is concentrating on improving patient outcomes in oncology and increasing shareholder value through strategic initiatives and partnerships.

How Jounce Therapeutics, Inc. (JNCE) Makes Money

Revenue Streams

Jounce Therapeutics generates revenue primarily through:

• Partnerships and collaborations
• Grants and funding
• Potential product sales upon drug approval

Partnerships and Collaborations

Jounce has established several collaborations with large pharmaceutical companies to develop its proprietary therapies. A notable collaboration includes:

• Celgene (Bristol-Myers Squibb): In 2018, Jounce entered into a partnership with Celgene worth up to $225 million. This includes an upfront payment, milestone payments, and royalties on future sales.

Grants and Funding

Jounce receives non-dilutive funding from various sources including federal grants. In 2021, Jounce was awarded a grant from the National Cancer Institute valued at approximately:

• $1.5 million

Potential Product Sales

The company is working on several drug candidates that, if approved, would contribute significantly to revenue. As of October 2023, here are some of the prominent candidates:

Financial Performance

As of the end of Q2 2023, Jounce reported the following financial figures:

Stock Performance

As of October 2023, Jounce's stock performance has shown significant volatility. The stock price as of the last market close was:

• $4.15

The market capitalization stood at approximately:

• $200 million

Future Opportunities

Jounce is focusing on expanding its pipeline and increasing partnerships. The potential market for their lead candidates could be valued at:

• $1 billion annually if successful in late-stage trials and subsequent commercialization.